GPT and COVID-19: Among laboratory markers measured during the acute phase of COVID-19, patients with PCPF had significantly higher hemoglobin levels than those without the condition (median 12.0 g/dL [IQR: 9.8–14.1] vs. 10.6 g/dL [IQR: 9.1–12.6], p = 0.001) and alanine aminotransferase (ALT) (median 30.0 IU/L [IQR: 18.5–45.5] vs. 21.0 IU/L [IQR: 13.0–36.0], p = 0.001).